The management of dyslipidaemias in antiretroviral-treated HIV infection: A systematic review

HIV Medicine

Volumn 8, Issue 6, 2007, Pages 325-334

  McGoldrick, C ^a   Leen, C L S ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Antiretroviral; Dyslipidaemia; Management; Review

Indexed keywords

ABACAVIR; ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; BEZAFIBRATE; CHOLESTIN; DIDANOSINE; EFAVIRENZ; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; INSULIN SENSITIZING AGENT; LOPINAVIR PLUS RITONAVIR; METFORMIN; NEVIRAPINE; PLACEBO; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSIGLITAZONE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ABDOMINAL PAIN; BODY BUILD; CD4 LYMPHOCYTE COUNT; CLINICAL PROTOCOL; CLINICAL TRIAL; COCHRANE LIBRARY; DEPRESSION; DIARRHEA; DISORIENTATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPNEA; EMBASE; FACE EDEMA; FANCONI RENOTUBULAR SYNDROME; FATIGUE; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INDIGESTION; INSOMNIA; LIBIDO DISORDER; MALAISE; MEDLINE; MENTAL DISEASE; NAUSEA; NEPHROLITHIASIS; NEUROLOGIC DISEASE; PANCREATITIS; PNEUMONIA; POLYNEUROPATHY; PRIORITY JOURNAL; PRURITUS; REVIEW; SIDE EFFECT; TACHYCARDIA; TOXIC HEPATITIS; URINARY TRACT INFECTION;

ANTI-RETROVIRAL AGENTS; ANTILIPEMIC AGENTS; DRUG ADMINISTRATION SCHEDULE; DYSLIPIDEMIAS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION THERAPY MANAGEMENT;

EID: 34547453648     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2007.00480.x     Document Type: Review

References (47)

1. Lenhard JM, Furfine ES, Jain RG et al. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. Antivir Res 2000; 47: 121-129.
2. Zhang B, Macnaul K, Szalkowski D, Li Z, Berger J, Moller DE. Inhibition of adipocyte differentiation by HIV protease inhibitors. J Clin Endocrinol Metab 1999; 84: 4274-4277.
3. Staszewski S, Morales-Ramirez J, Tashima KT et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999; 341: 1865-1873.
4. Domingo P, Labarga P, Palacios R et al. Improvement of dyslipidemia in patients switching from stavudine to tenofovir: Preliminary results. AIDS 2004; 18: 1475-1478.
5. Constans J, Pellegrin JL, Peuchant E et al. Plasma lipids in HIV-infected patients: A prospective study in 95 patients. Eur J Clin Invest 1994; 24: 416-420.
6. Grunfeld C, Kotler DP, Shigenaga JK et al. Circulating interferon-alpha levels and hypertriglyceridaemia in the acquired immunodeficiency syndrome. Am J Med 1991; 90: 154-162.
7. El-Sadr WM, Mullin CM, Carr A et al. Effects of HIV disease on lipid, glucose and insulin levels: Results from a large antiretroviral-naïve cohort. HIV Med 2005; 6: 114-121.
8. Carr A, Samaras S, Burton M et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F58.
9. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74: 1045-1052.
10. Purnell JQ, Zambon A, Knopp RH et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000; 14: 51-57.
11. Zangerle R, Sarcletti M, Gallati H, Reibnegger G, Wachter H, Fuchs D. Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation. J Acquir Immune Defic Syndr 1994; 7: 1149-1156.
12. Grinspoon SK. Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus. Am J Med 2005; 118 (Suppl. 2): 23S-28S.
13. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J Am Med Assoc 2001; 285: 2486-2497.
14. Palella FJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860.
15. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
16. Henry K, Melroe H, Huebusch J, Hermundson J, Simpson J. Atorvastatin and gemfibrozil for protease inhibitor-associated lipid abnormalities. Lancet 1998; 325: 1031-1032.
17. Tonkin A, Aylward P, Colquhoun D et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349-1357.
18. Grundy SM. Cholesterol metabolism in man. West J Med 1978; 128: 13-25.
19. Fichtenbaum CJ, Gerber JG, Rosenkranz SL et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 2002; 16: 569-577.
20. Van Der Lee M, Vogel M, Schippers E et al. Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, February 2006 [Abstract 588].
21. Miller NE. Pharmacological intervention for altering lipid metabolism. Drugs 1990; 40 (Suppl. 1): 26-31.
22. Goa KL, Baradell LB, Plosker GL. Bezafibrate: An update of its pharmacology and use in the management of dyslipidaemia. Drugs 1996; 52: 725-753.
23. Frick MH, Elo O, Haapa K et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidaemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-1245.
24. Robins SJ, Collins D, Wittes JT et al. Relation of gemfibrozil treatment anA lipid levels with major coronary events: VA-HIT: a randomized controlled trial. J Am Med Assoc 2001; 285: 1585-1591.
25. Martinez E, Conget I, Lozano L, Casamitjana R, Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999; 13: 805-810.
26. Derosa G, Cicero AF, Gaddi A et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: A twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther 2004; 26: 744-754.
27. Gerber MT, Mondy KE, Yarasheski KE et al. Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy. Clin Infect Dis 2004; 39: 419-425.
28. Gerber J, Kitch D, Aberg J et al. The safety and efficacy of fish oil in combination with fenofibrate in subjects on ART with hypertriglyceridemia who had an incomplete response to either agent alone: Results of ACTG A5186. 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, February 2006 [Abstract 146].
29. Negredo E, Rey-Joly C, Puig J et al. Ezetimibe, a selective inhibitor of cholesterol absorption, as a new strategy for treatment of hypercholesterolemia secondary to antiretroviral therapy. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, December 2005 [Abstract H-336].
30. Ezzat S, Fear S, Gaillard RC et al. Gender-specific responses of lean body composition and non-gender specific cardiac function improvement following GH replacement in GH-deficient adults. J Clin Endocrinol Metab 2002; 87: 2725-2733.
31. Kotler DP, Muurahainen N, Grunfeld C et al. Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidaemia in HIV-infected patients. J Acquir Immune Defic Syndr 2004; 35: 239-252.
32. Reaven P, Herold D, Barnett J, Edelman S. Effects of vitamin E on susceptibility of low density lipoprotein and low density lipoprotein subfractions to oxidation and on protein glycation in NIDDM. Diabetes Care 1995; 18: 807-816.
33. Calza L, Manfredi R, Chiodo F. Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. AIDS 2003; 17: 851-859.
34. Moyle GJ, Lloyd M, Reynolds B, Baldwin C, Mandalia S, Gazzard BG. Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy. AIDS 2001; 15: 1503-1508.
35. Keithley JK, Swanson B, Sha BE, Zeller JM, Kessler HA, Smith KY. A pilot study of the safety and efficacy of cholestin in treating HIV-related dyslipidaemia. Nutrition 2002; 18: 201-204.
36. Calza L, Manfredi R, Chiodo F. Use of fibrates in the management of hyperlipidaemia in HIV-infected patients receiving HAART. Infection 2002; 30: 26-31.
37. Badiou S, De Boever CM, Dupuy A, Baillat V, Cristol JP, Reynes J. Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults. Atherosclerosis 2004; 172: 273-279.
38. Miller J, Brown D, Amin J et al. A randomised, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia. AIDS 2002; 16: 2195-2200.
39. Walli R, Michl M, Bogner JR, Goebel FD. Improvement of HAART-associated insulin resistance and dyslipidaemia after replacement of protease inhibitors with abacavir. Eur J Med Res 2001; 6: 413-421.
40. Moyle GJ, Baldwin C, Langroudi B, Mandalia S, Gazzard BG. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidaemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr 2003; 33: 22-28.
41. Fisac C, Fumero E, Crespo M et al. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS 2005; 19: 917-925.
42. Keiser PH, Sension MG, DeJesus E et al. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment. BMC Infect Dis 2005; 5: 2.
43. Negredo E, Ribalta J, Paredes R et al. Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS 2002; 16: 1383-1389.
44. Calza L, Manfredi R, Colangeli V et al. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS 2005; 19: 1051-1058.
45. TomažiěJ, Karner P, Vidmar L, MatiěiěM, Sharma PM, Janež A. Effect of metformin and rosiglitazone on lipid metabolism in HIV infected patients receiving protease inhibitor containing HAART. Acta Dermatovenerol Alp Panonica Adriat 2005; 14: 99-105.
46. Martinez E, Arnaiz JA, Podzamczer D et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003; 349: 1036-1046.
47. Aberg JA, Zackin RA, Brobst SW et al. A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res Hum Retroviruses 2005; 9: 757-767.